PONTE VEDRA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “&CloseCurlyDoubleQuote Company”;) (NasdaqGS: TMCI), a medical technology company behind a fundamental change in the surgical field for the treatment of hallux valgus (commonly known as bunions), announces that it will highlight new product innovations at the 2022 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting in Quebec City , Canada, September 14-17.1
Several technologies will be highlighted on the Treace’ stand (n°301) during the AOFAS conference, in particular:
- Lapiplasty® Micro-Incision™ System: Lapiplasty® The Micro-Incision™ System is a set of state-of-the-art instruments specially developed to reduce the size of the incision required to perform Lapiplasty® 3D Bunion Correction™ Procedure. State-of-the-art instrument set, including the Lapiplasty® 3-n-1™ Micro-Incision™ guide and other specialized surgical instruments enable the deformity correction and joint preparation stages of patented Lapiplasty® Procedure to be performed through incisions of 2 cm or less. Lapiplasty® Micro-Incision™ instrumentation is currently in limited clinical access.
- SpeedPlate™ Rapid Compression Implants: The SpeedPlate™ Implant System represents a new platform in Lapiplasty® fixation technology, providing foot and ankle surgeons with additional fixation options for lapiplasty® and adductoplasty™ procedures. SpeedPlate™ implants are designed for rapid fixation application while providing dynamic compression of articular surfaces. This new fixation platform is compatible with the Lapiplasty® Micro-Incision™ Surgical Approach. The patent-pending SpeedPlate™ system has undergone FDA 510(k) review and is not yet available for sale in the United States
- New Lapiplasty® New: Newly commercialized innovations will also be showcased at Treace’s booth and in hands-on training workshops, including the Lapiplasty® S4A Anatomic Veneer Kit, Lapiplasty® 3-n-1™ Guide and SpeedRelease Tissue Release Instruments ™ and TriTome™. These new technologies are available in full commercial version.
John T. Treace, CEO, Founder and Member of the Board of Directors of Treace, said, “As the only company in the industry solely focused on advancing the standard of care in the surgical correction of bunion and associated midfoot deformities, we are excited to present our latest R&D innovations to surgeons attending the AOFAS 2022 conference. These new technologies demonstrate Treace’s commitment to rapid innovation with a focus on continuous iteration of the Lapiplasty® System with options to reduce incision size and increase procedure efficiency while maintaining the clinical outcomes associated with the Lapiplasty® Procedure.”
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company focused on advancing the standard of care for the surgical management of bunions and associated midfoot deformities. Bunions are complex three-dimensional deformities that originate from an unstable joint in the midfoot and affect approximately 65 million Americans, of whom Treace estimates that 1.1 million are annual surgical candidates. Treace pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, by s attacking the root cause of bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ midfoot correction system, designed for reproducible surgical correction of the midfoot to provide additional support for patients with hallux valgus. For more information, please visit www.treace.com.
About the AOFAS Scientific Conference
The American Orthopedic Foot & Ankle Society® (AOFAS) mobilizes its global community of foot and ankle orthopedic specialists to improve patient care through education, research and advocacy. The AOFAS Annual Meeting is the premier event for foot and ankle education, featuring presentations from renowned speakers, special interest forums, and the latest products and technologies.
- Treace products will be shown in Canada for demonstration purposes only. They are not permitted under Canadian regulations.
contacts:
Treace Medical Concepts, Inc.
Mark L.Hair
Financial director
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
[email protected]
